Obe-25ulcerative colitisObe-25-PBOObe-50ObefazimodObeObe-50-PBO
…rted at least one TEAE were 59.4%, 46.9%, and 53.2% for Obe-50, Obe-25, and PBO, respectively in ABTECT-1 and 61.0%, 50.9%, and 48.4% …
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Funders
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentions29,499matching articles
244,054matching entity mentions
30popular entities listed
0%of mentions human-reviewed
Popular entities in these results
Choose an entity to see the articles in which it was identified.
EMBASE784PUBMED717COVID-19645Cancer605SLE570Diabetes552NHS522WEB OF SCIENCE499Hypertension418SCOPUS417HIV406Systemic Lupus Erythematosus390Heart Failure364Asthma349Stroke336COPD331WHO330Colorectal Cancer327Cardiovascular Disease317Type 2 Diabetes316Chronic Obstructive Pulmonary Disease313Joanna Briggs Institute306MEDLINE306Atrial Fibrillation283Cochrane Library275Breast Cancer271Hepatocellular Carcinoma253SSc251Inflammatory Bowel Disease250Obesity246
Matching articles
29,499 articles · page 40 of 2459Allopurinolinflammatory bowel diseaseUniversity Hospitals DorsetAZAazathioprineAutoimmune hepatitis (AIH)
….56SFR 46 (59.7%)13 (68.4%)p= 0.59Mann Whitney U 6-TGN pre/post Allopurinol (mean)222.3- 396.2p = 0.00296-MMPN level pre/post allopurinol (…
mesalazineulcerative colitisCrohn’s diseaseIBD-Uinflammatory bowel diseaseLeeds Teaching HospitalsIBD
…was 13.1 years. Patients with IBD-U were less likely to receive mesalazine (85%) compared with UC (92%, p=0.0058) but more likely than pat…
obesitymyosteatosisHFpEFHFpEFObeseNon-obeseAge
…nction and exercise intolerance observed in HFpEF patients with obesity. However, limited sample size may restrict our ability to gener…
cancercyclophosphamidemycophenolateSScmethotrexate
…) and negatively with digital ulcers (OR 0.4; CI 0.2-0.7). Lung cancer was associated with disease duration (OR 1.04; CI 1-1.08), smok…
TAs
… presented lower LFTs parameters.Conclusions Our data show that TAs are associated with a more aggressive SSc phenotype from both a…
98.8%
type 2 diabetestype 1 diabetesinsulindiabetes
…time-in-range (SMD 0.78, −0.01 to 1.57; moderate certainty). In type 2 diabetes, men were more likely to achieve HbA1c targets (RR 0.86, 95% CI…
ustekinumabinfliximabadalimumabUlcerative colitisADAIFXIBDUSTCrohn’s disease
…erval (33.3%) and to restart the drug (25.0%). In patients with ustekinumab, the main interventions were to shorten the dosing interval (55…
hypoalbuminaemiaOrion Clinicvalproic acidVAFVPA
…and Importance Valproic acid (VA) binds strongly to albumin. In hypoalbuminaemia, the free valproic acid fraction (FVPA) – the pharmacologically…
ErelziBenepaliEnbrelRheumatoid arthritisetanerceptRAEQ-5D
…nt, and 43% worsening in perceived health status post-switch to Erelzi. Ten suspected adverse drug reactions were reported since IPC i…
durvalumabPembrolizumabdostarlimabatezolizumabOlaparibpMMRendometrial cancer
…erapy –specifically those including pembrolizumab, dostarlimab, durvalumab, durvalumab plus olaparib, and atezolizumab–, in the treatment …
apixabanrivaroxabanedoxabanDabigatran
…ement.Results A total of 1,992 drug interactions were analysed: apixaban 531 (26.7%), dabigatran 492 (24.7%), edoxaban 411 (20.6%), riva…